Bearish
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
Context Therapeutics (NASDAQ: CNTX) announced interim Phase 1 data for its drug CTIM-76, showing a 29% overall response rate and 57% disease control r...